FDA Approves Higher-Dose Wegovy HD for Weight Loss

Washington, D.C. — The U.S. Food and Drug Administration on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy, offering patients the potential for greater weight loss than previously available formulations. The approval was granted just 54 days after filing under the FDA’s accelerated National Priority Voucher program. Reports from the FDA, the Associated Press, Novo Nordisk, Pharmacy Times, FiercePharma, and Reuters-affiliated outlets contributed to this report. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we curated on this story.

Core Facts

• The FDA approved Wegovy HD, a 7.2-milligram dose of semaglutide, on March 19, 2026. This represents a significant increase from the previous maximum approved dose of 2.4 milligrams.
• The approval was granted under the FDA’s Commissioner’s National Priority Voucher pilot program, an accelerated review pathway for products addressing critical national health priorities. The entire review process took only 54 days from filing to approval.
• Clinical trial data from the 72-week STEP UP study demonstrated that patients receiving the 7.2 mg dose achieved an average weight loss of 20.7 percent if all patients stayed on treatment, compared to 17.5 percent with the 2.4 mg dose and 2.4 percent with placebo.
• Approximately 31.2 percent of trial participants taking Wegovy HD achieved weight loss of 25 percent or higher, more than double the 15.3 percent who reached this threshold at the 2.4 mg dose.
• Novo Nordisk expects to launch Wegovy HD in U.S. pharmacies in April 2026. The higher dose formulation has already received regulatory approval in the United Kingdom and European Union.
• The most commonly reported adverse reactions were gastrointestinal in nature, including nausea, vomiting, constipation, and abdominal pain. A condition involving altered skin sensation known as dysesthesia occurred at a substantially higher rate with the 7.2 mg dose compared to lower doses.

Additional Details Reported

Wegovy HD is indicated for adults with obesity who have tolerated the 2.4 mg dosage for at least four weeks and for whom additional weight reduction is clinically indicated. The medication is a glucagon-like peptide-1 receptor agonist that works by mimicking a natural gut hormone to help regulate appetite and reduce food intake.

Dr. Jody Dushay, an endocrinologist and obesity expert at Harvard Medical School, noted that the higher dose may be especially helpful for people who are tolerating the lower-dose version but have had suboptimal weight loss. She also suggested it could benefit patients who do not have a robust response to competing obesity medications.

The FDA approval carries a boxed warning regarding potential risk of thyroid C-cell tumors based on findings in rodent studies. The medication should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

According to study data, more than 70 percent of patients taking the higher dose reported side effects such as nausea, vomiting, and constipation, compared to more than 60 percent taking the lower dose and about 43 percent taking placebo. Serious adverse events were reported in nearly 7 percent of those taking the 7.2-milligram dose.

Wegovy is the only GLP-1 medication approved to reduce the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with known heart disease and obesity or overweight.

How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.